您的位置:山东大学 -> 科技期刊社 -> 《山东大学学报(医学版)》

山东大学学报 (医学版) ›› 2020, Vol. 58 ›› Issue (3): 44-51.doi: 10.6040/j.issn.1671-7554.0.2020.179

• • 上一篇    下一篇

山东省新型冠状病毒肺炎患者537例临床特征与救治效果

周生余1,2,王春亭3,张伟4,王锡明5,董亮1   

  • 出版日期:2020-03-10 发布日期:2022-09-27
  • 通讯作者: 董亮. E-mail:dl5506@126.com
  • 基金资助:
    山东省重点研发计划(2020SFXGFY03-1,2020SFXGFY03-3,2020SFXGFY04)

Clinical characteristics and treatment effect of 537 cases of novel coronavirus pneumonia in Shandong Province

ZHOU Shengyu1,2, WANG Chunting3, ZHANG Wei4, WANG Ximing5, DONG Liang1   

  1. 1. Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China;
    2. School of Nursing, Shandong University, Jinan 250012, Shandong, China;
    3. Department of Critical Care Medicine, Shandong Provincial Hospital, Jinan 250021, Shandong, China;
    4. Department of Lung Disease, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, Shandong, China;
    5. Department of Radiology, Shandong Provincial Hospital, Jinan 250021, Shandong, China
  • Online:2020-03-10 Published:2022-09-27

摘要: 目的 提高山东省新型冠状病毒肺炎诊治水平。 方法 对截止到2020年2月15日的山东省新型冠状病毒感染的肺炎患者的发病临床资料进行汇总,研究患者的基本状况、临床特点、治疗方案和治疗效果等,并结合4例典型病例进行总结分析。 结果 新型冠状病毒肺炎在山东的流行病学特点、临床症状和治疗方面与全国基本一致。绝大多数患者为轻型和普通型,少数为重型,极少数危重型患者合并严重的基础疾病。患者临床表现以发热、干咳为主,血常规白细胞正常或降低,约半数患者淋巴细胞降低,发病初期胸部CT以磨玻璃影为主,总体治疗效果满意。高龄和基础疾病是导致病情不断进展的重要因素,密切观察由普通型向重型及危重型发展的征象,及早给予干预,可提高救治成功率。 结论 山东省新型冠状病毒肺炎发生率偏高,但普通型居多,重型低于湖北以外全国平均水平。危重型救治成功率高,死亡率低于湖北以外全国平均水平。山东省临床救治经验应该在国内推广应用。

关键词: 山东省, 新型冠状病毒肺炎, 临床特征, 救治效果

Abstract: Objective To provide valuable references for improving the diagnosis and treatment of novel coronavirus pneumonia in Shandong Province. Methods Clinical data of novel coronavirus pneumonia(NCP)patients in Shandong Province until February 15, 2020 were summarized and analyzed to investigate their epidemiological and clinical features and treatment effect. Furthernore, the clinical data of four typical cases were presented in detail. Results The characteristics of the epidemic, clinical symptoms and treatment were basically consistent with the national data. The vast majority of patients were mild, a few were severe, and very few were critically ill because of severe underlying diseases. Clinical features were mainly fever, dry cough, normal or decreased levels of white blood cells, about 50 percent of cases with reduced lymphocyte count, and ground glass opacity in lung in the early stage. The treatment effect was generally satisfactory. Senility and underlying diseases were important risk factors for severe illness. Closely observing the signs of disease progression and early intervention could reduce mortality. Coclusion The incidence of NCP in Shandong Province is relatively high, but the majority are common type, and the severe type is lower than the national average level outside Hubei Province. The survival rate of severe case is high, and the mortality is lower than the national average level outside Hubei Province. The therapeutic experience of Shandong Province should be promoted and applied in China.

Key words: Shandong Province, Novel coronavirus pneumonia, Clinical characteristics, Treatment effect

中图分类号: 

  • R563.1
[1] Paules CI, Marston HD, Fauci AS. Coronavirus infections-more than just the common cold[J]. JAMA, 2020. doi:10.1001/jama.2020.0757.
[2] Hui DS, I Azhar E, Madani TA. et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China[J]. Int J Infect Dis, 2020: 264-266. doi: 10.1016/j.ijid.2020.01.009.
[3] 武汉市卫生健康委员会. 武汉市卫健委关于当前我市肺炎疫情的情况通报[EB/OL].(2019-12-31)[2020-02-19].http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989.
[4] WHO. Novel coronavirus-China[EB/OL].(2020-01-12)[2020-02-19]. http://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/.
[5] 国卫办医函. 关于印发新型冠状病毒感染的肺炎诊疗方案(试行第二版)的通知[EB/OL]. http://www.nhc.gov.cn/yzygj/ggwsylglc/new_list_2.shtml.
[6] 国卫办医函. 关于印发新型冠状病毒感染的肺炎诊疗方案(试行版)的通知[EB/OL]. http://www.nhc.gov.cn/yzygj/ggwsylglc/new_list_2.shtml.
[7] 国卫办医函. 《国家卫生健康委办公厅关于印发新型冠状病毒的肺炎诊疗方案(试行第二版)和全国各省(区、市)首例新型冠状病毒感染的肺炎病例确认程序的通知》[EB/OL].(2020-01-18)[2020-02-19].http://www.nhc.gov.cn/yzygj/ggwsylglc/new_list_2.shtml.
[8] Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV)infected pneumonia(standard version)[J]. Mil Med Res, 2020, 7(1): 4. doi:10.1186/s40779-020-0233-6.
[9] 国卫办医函. 关于印发新型冠状病毒肺炎诊疗方案(试行第五版 修正版)的通知[EB/OL].(2020-02-08)[2020-02-19]. http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728f-caf1e3e13a.shtml.
[10] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506.
[11] Chen N, Zhou M, Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223): 507-513.
[12] Guan, WJ, Ni ZY, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China[J]. N Engl J Med, 2020. doi: 10.1056/NEJMoa2002032.
[13] Wang G, Jin X. The progress of 2019 novel coronavirus event in China[J]. J Med Virol, 2020. doi:10.1002/jmv.25705.
[14] 国卫办医函. 关于印发新型冠状病毒感染的肺炎诊疗方案(试行第三版)的通知[EB/OL].(2020-01-22)[2020-02-19]. http://www.nhc.gov.cn/yzygj/s7653p/202001/f492c9153ea9437bb-587ce2ffcbee1fa.shtml.
[15] 国卫办医函. 关于印发新型冠状病毒感染的肺炎诊疗方案(试行第四版)的通知[EB/OL].(2020-01-27)[2020-02-19]. http://www.nhc.gov.cn/yzygj/s7653p/202001/4294563ed35b432-09b31739bd0785e67.shtml.
[16] Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically Ill patients with Middle East respiratory syndrome: a multicenter observational study[J]. Clin Infect Dis, 2019. doi: 10.1093/cid/ciz544..
[17] Zumla A, Bates M, Maeurer M. Corticosteroid therapy for pneumonia[J]. Lancet, 2015, 386(9997): 955. doi:10.1016/s0140-6736(15)00065-3.
[18] Ling Y, Xu SB, Lin YX, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients[J]. Chin Med J(Engl), 2020. doi:10.1097/cm9.0000000000000774.
[19] Arabi YM, Arifi AA, Balkhy HH, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection[J]. Ann Intern Med, 2014, 160(6): 389-397.
[1] 巩雨,高震,王虎清,杨晶雯,张桂莲,展淑琴,张茹,吴海琴. 4例继发性肥大性下橄榄核变性的临床及影像学特点[J]. 山东大学学报 (医学版), 2022, 60(5): 37-42.
[2] 曹义海. 血管生成在疾病治疗中的应用与展望[J]. 山东大学学报 (医学版), 2021, 59(9): 9-14.
[3] 杨璇,李岩志,马伟,贾崇奇. 基于两样本孟德尔随机化的肺功能与新型冠状病毒肺炎病死风险的因果关系[J]. 山东大学学报 (医学版), 2021, 59(7): 104-111.
[4] 周溪,黄霂晗,任玉洁,邱洋. 新型冠状病毒感染与天然免疫及炎症反应[J]. 山东大学学报 (医学版), 2021, 59(5): 15-21.
[5] 于莹,张功,刘晶,颜世童,韩涛,黄海量. 基于网络药理学和分子对接方法探析黄芪预防新型冠状病毒肺炎的潜在作用机制[J]. 山东大学学报 (医学版), 2021, 59(4): 6-16.
[6] 任敏敏,王广梅,张丽,杨瑶瑶,封丹珺. 335名抗疫一线护理人员心理弹性对共情疲劳的影响[J]. 山东大学学报 (医学版), 2021, 59(2): 88-94.
[7] 游雪婷,田兴松. 3 514例乳腺癌9年间临床及病理学特征分析[J]. 山东大学学报 (医学版), 2021, 59(1): 49-54.
[8] 山东大学齐鲁医院新型冠状病毒肺炎诊治专家组. 新型冠状病毒肺炎疑似病例诊断及管理专家共识·齐鲁医院标准[J]. 山东大学学报 (医学版), 2020, 58(3): 1-7.
[9] 山东大学齐鲁医院新型冠状病毒肺炎防控工作组. 山东大学齐鲁医院新型冠状病毒肺炎防控策略与实践[J]. 山东大学学报 (医学版), 2020, 58(3): 8-18.
[10] 李士雪,单莹. 新型冠状病毒肺炎研究进展述评[J]. 山东大学学报 (医学版), 2020, 58(3): 19-25.
[11] 鞠秀丽. 间充质干细胞治疗新型冠状病毒肺炎的潜在机制和研究进展[J]. 山东大学学报 (医学版), 2020, 58(3): 32-37.
[12] 崔亮亮,耿兴义,赵小冬,杨国樑,常彩云,赵梦娇,李战,王春荣,刘岚铮,阮师漫. 济南市现阶段新型冠状病毒肺炎的流行特征与思考[J]. 山东大学学报 (医学版), 2020, 58(3): 52-57.
[13] 张孝国,马艳,肖嘉安,张忠法. 济南市儿童新型冠状病毒肺炎的临床特征[J]. 山东大学学报 (医学版), 2020, 58(3): 62-64.
[14] 余雪源,张硕,燕芳芳,苏德振. 采用清肺排毒汤联合西药43例与单用西药46例的新型冠状病毒肺炎临床疗效比较[J]. 山东大学学报 (医学版), 2020, 58(12): 47-53.
[15] 牛占丛,王彦霞,王晓亚,王晓庆,李亚轻,边竞. 新型冠状病毒肺炎2例报告[J]. 山东大学学报 (医学版), 2020, 58(10): 134-136.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!